Verition Fund Management’s Edwards Lifesciences EW Stock Holding History

Verition Fund Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,200	Closed	-$955K	–	2683
2025 Q4	$955K	Sell	11,200 -39,500	-78%	-$3.24M	﹤0.01%	2187
2025 Q3	$3.94M	Buy	50,700 +2,900	+6%	+$227K	0.02%	1392
2025 Q2	$3.74M	Buy	47,800 +3,100	+7%	+$231K	0.02%	1410
2025 Q1	$3.24M	Buy	44,700 +29,400	+192%	+$2.1M	0.02%	1213
2024 Q4	$1.13M	Sell	15,300 -5,300	-26%	-$371K	﹤0.01%	1965
2024 Q3	$1.36M	Hold	20,600	–	–	0.01%	1669
2024 Q2	$1.9M	Buy	20,600 +12,800	+164%	+$1.13M	0.01%	1300
2024 Q1	$745K	Buy	+7,800	New	+$655K	0.01%	1783
2023 Q3	–	Sell	-2,400	Closed	-$226K	–	2442
2023 Q2	$226K	Buy	+2,400	New	+$209K	﹤0.01%	1753
2023 Q1	–	Sell	-4,700	Closed	-$351K	–	2259
2022 Q4	$351K	Hold	4,700	–	–	0.01%	1414
2022 Q3	$388K	Buy	+4,700	New	+$452K	﹤0.01%	2056
2022 Q2	–	Sell	-8,700	Closed	-$1.02M	–	2562
2022 Q1	$1.02M	Buy	8,700 +6,700	+335%	+$752K	0.01%	1439
2021 Q4	$259K	Buy	+2,000	New	+$233K	﹤0.01%	2076

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Verition Fund Management's EW Position: Q1 2026 in Review

Verition Fund Management reduced its Edwards Lifesciences (EW) stake by 96% in Q1 2026, selling an estimated $12.1M and leaving 6,040 shares worth $484K. The position accounts for ﹤0.01% of the portfolio, ranked #1603.

Verition Fund Management first reported a position in EW in Q3 2013 and has held it in 33 quarters since. The position peaked at $13M in Q4 2025. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Verition Fund Management held 6,040 shares of Edwards Lifesciences worth $484K as of Q1 2026.
Verition Fund Management sold 146,316 Edwards Lifesciences shares in Q1 2026, an estimated $12.1M.
Edwards Lifesciences made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1603 holding.
Verition Fund Management first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 33 quarters since.
Verition Fund Management's Edwards Lifesciences position peaked at $13M in Q4 2025.
1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.